Cellectis SA (NASDAQ: CLLS) — Perfil da empresa, notícias e dados financeiros
Cellectis is a biopharmaceutical company focused on immunotherapies using gene-edited T-cells to target cancer.
Cellectis SA
Cellectis (EPA:ALCLS), (NASDAQ:CLLS) is a biopharmaceutical company focused on developing immunotherapies based on gene-edited T-cells, using its pioneering TALEN technology and CRISPR-Cas9. The company is headquartered in Paris, France, and operates globally, aiming to harness the power of the immune system to target and eradicate cancers. Cellectis is also known for its innovative approach in the field of gene editing, endeavoring to create more effective and safer therapies for patients worldwide. Its project portfolio includes multiple pre-clinical and clinical trials, focusing primarily on CAR-T cell therapies, a groundbreaking approach in cancer treatment. Cellectis is driven by the objective to make accessible life-saving UCART product candidates to address unmet needs in the treatment of multiple aggressive cancers.
Resumo
Operações
Produtos e/ou serviços de Cellectis SA
- UCART19, an engineered T-cell product targeting CD19-expressing malignancies.
- ALLO-501, aimed at treating non-Hodgkin lymphoma through modified T-cells.
- TALLEN, a gene-editing technology for precision genome modifications.
- UCART123, developed for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm.
- UCART22, designed for B-cell acute lymphoblastic leukemia therapy.
- BALLI-01 trial, assessing the safety and efficacy of UCART22 in B-ALL patients.
equipe executiva do Cellectis SA
- Andre ChoulikaCo-Founder, CEO & Director
- David J. SourdiveCo-Founder, Deputy CEO, Executive VP of CMC & Manufacturing and Director
- Arthur StrilCFO & Chief Business Officer
- Valerie CrosPrincipal Financial Officer & Principal Accounting Officer
- Jean Charles EpinatChief Technological Officer
- Philippe DuchateauChief Scientific Officer
- Marie-Bleuenn TerrierGeneral Counsel & Secretary of the Board of Directors
- Pascalyne WilsonDirector of Communications
- Kyung Nam-WortmanExecutive VP & Chief Human Resources Officer
- Stephan ReynierChief Regulatory & Pharmaceutical Compliance Officer
Principais indicadores financeiros
Resultados divulgados pela Cellectis SA, em USD.
- Cap. de mercado
- 126,9 mi
- Receita (TTM)
- 63,8 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.6
- Dividend yield
- —
- Margem de lucro
- -102.3%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 72,9 mi | -33,1 mi | -67,6 mi | |
| 41,5 mi | -59,6 mi | -36,8 mi | |
| 755 mil | -97,3 mi | -101,1 mi | |
| 19,2 mi | -89,7 mi | -98,7 mi |